- Home
- CRBP vs NTHI Comparison
CRBP vs NTHI Comparison
Compare CRBP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NTHI
- Stock Information
- Founded
- CRBP 2009
- NTHI 2008
- Country
- CRBP United States
- NTHI United States
- Employees
- CRBP N/A
- NTHI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- NTHI Health Care
- Exchange
- CRBP Nasdaq
- NTHI Nasdaq
- Market Cap
- CRBP 96.5M
- NTHI 110.9M
- IPO Year
- CRBP N/A
- NTHI N/A
- Fundamental
- Price
- CRBP $8.22
- NTHI $4.75
- Analyst Decision
- CRBP Strong Buy
- NTHI
- Analyst Count
- CRBP 10
- NTHI 0
- Target Price
- CRBP $53.56
- NTHI N/A
- AVG Volume (30 Days)
- CRBP 215.8K
- NTHI 272.8K
- Earning Date
- CRBP 08-05-2025
- NTHI 01-01-0001
- Dividend Yield
- CRBP N/A
- NTHI N/A
- EPS Growth
- CRBP N/A
- NTHI N/A
- EPS
- CRBP N/A
- NTHI N/A
- Revenue
- CRBP N/A
- NTHI $79,990.00
- Revenue This Year
- CRBP N/A
- NTHI N/A
- Revenue Next Year
- CRBP $270.04
- NTHI N/A
- P/E Ratio
- CRBP N/A
- NTHI N/A
- Revenue Growth
- CRBP N/A
- NTHI 13.52
- 52 Week Low
- CRBP $4.64
- NTHI $3.20
- 52 Week High
- CRBP $61.90
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- NTHI N/A
- Support Level
- CRBP $7.26
- NTHI N/A
- Resistance Level
- CRBP $7.90
- NTHI N/A
- Average True Range (ATR)
- CRBP 0.53
- NTHI 0.00
- MACD
- CRBP -0.01
- NTHI 0.00
- Stochastic Oscillator
- CRBP 78.59
- NTHI 0.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").